SALT LAKE CITY, April 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, revealed results from a multi-year, real-world study of ...
Myriad Genetics MYGN is well poised for growth in the coming quarters ... In the past six months, this Zacks Rank #3 (Hold) stock has gained 32.8% compared with a 0.6% rise of the industry and a 20% ...
Myriad Genetics psychotropic test 'GeneSight' linked to lower hospitalization in depression patients
One of the key InvestingPro Tips for Myriad Genetics is the company's stock price volatility, which investors should be aware of when considering adding MYGN to their portfolio. The company's ...
Nio, XPeng, Baidu Are Trading Near 52-Week Lows: Which Chinese Stock Has More Upside? Analyst ratings measure the expected performance of a stock during a given time period. Analysts and brokerage ...
Exchanges worldwide provide access, enabling dual listings for broader trading options. Stock exchanges are places where people buy and sell shares of stock. Companies agree to have their shares ...
Myriad Genetics psychotropic test 'GeneSight' linked to lower hospitalization in depression patients
One of the key InvestingPro Tips for Myriad Genetics is the company's stock price volatility, which investors should be aware of when considering adding MYGN to their portfolio. The company's stock ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback